Analysis of Japanese Patients Treated with or without Long-Term Epirubicin Plus Ara-C Intravesical Instillation Therapy for Low-Grade Superficial Bladder Cancer

Figure 2

Comparison of recurrence-free survival between Instillation group (●) and TURBT-only group (○). Recurrence-free rate was significantly higher in the Instillation group than in the TURBT-only group (). The 1-, 3-, and 5-year recurrence-free rates were 80.6%, 69.7%, and 58.5% for the Instillation group and 61.2%, 43.4%, and 38.6% for the TURBT-only group.